Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Brief Summary: This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.


Options:
A: Arm Label: Dose Escalation Cohort: Avelumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 20.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: NSCLC, Post-platinum Doublet; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: NSCLC, First Line; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: Metastatic Breast Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: GC/GEJC Progressed; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: GC/GEJC Non Progressed; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Castrate-resistant Prostate Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Adrenocortical Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Melanoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Mesothelioma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Urothelial Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Ovarian Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Renal Cell Carcinoma (First Line); Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line); Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: Ovarian Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: Urothelial Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: GC/ GEJC, Third Line; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: HNSCC; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Intervention Type: DRUG; Name: Avelumab; Assigned to Arm(s): Dose Escalation Cohort: Avelumab 1.0 mg/kg, Dose Escalation Cohort: Avelumab 10.0 mg/kg, Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly, Dose Escalation Cohort: Avelumab 20.0 mg/kg, Dose Escalation Cohort: Avelumab 3.0 mg/kg, Efficacy Expansion Cohort: GC/ GEJC, Third Line, Efficacy Expansion Cohort: HNSCC, Efficacy Expansion Cohort: Ovarian Cancer, Efficacy Expansion Cohort: Urothelial Carcinoma, Primary Expansion Cohort: GC/GEJC Non Progressed, Primary Expansion Cohort: GC/GEJC Progressed, Primary Expansion Cohort: Metastatic Breast Cancer, Primary Expansion Cohort: NSCLC, First Line, Primary Expansion Cohort: NSCLC, Post-platinum Doublet, Secondary Expansion Cohort: Adrenocortical Carcinoma, Secondary Expansion Cohort: Castrate-resistant Prostate Cancer, Secondary Expansion Cohort: Colorectal Cancer, Secondary Expansion Cohort: Melanoma, Secondary Expansion Cohort: Mesothelioma, Secondary Expansion Cohort: Ovarian Cancer, Secondary Expansion Cohort: Renal Cell Carcinoma (First Line), Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line), Secondary Expansion Cohort: Urothelial Carcinoma
B: Arm Label: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab
C: Arm Label: Arm A: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Arm Label: Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel); Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: Paclitaxel, Drug: Vinflunine | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Arm A: Atezolizumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) | Intervention Type: DRUG; Name: Vinflunine; Assigned to Arm(s): Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab

Answer: C